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Abstract: In this both narrative and systematic review, we explore the role of TNF-α in the
immunopathogenesis of Behçet’s disease (BD) and the effect of treatment with TNF-α blockers. BD is
an auto-inflammatory disease, characterized by recurrent painful oral ulcerations. The pathogenesis
of BD is not yet elucidated; it is assumed that TNF-α may play a key role. In the narrative review,
we report an increased production of TNF-α, which may be stimulated via TLR-signaling, or triggered
by increased levels of IL-1β and IFN-γ. The abundance of TNF-α is found in both serum and in
sites of inflammation. This increased presence of TNF-α stimulates T-cell development toward
pro-inflammatory subsets, such as Th17 and Th22 cells. Treatment directed against the surplus
of TNF-α is investigated in the systematic review, performed according to the PRISMA guideline.
We searched the Pubmed and Cochrane database, including comparative studies only. After including
11 studies, we report a beneficial effect of treatment with TNF-α blockers on the various manifestations
of BD. In conclusion, the pivotal role of TNF-α in the immunopathogenesis of BD is reflected in both
the evidence of their pro-inflammatory effects in BD and in the evidence of the positive effect of
treatment on the course of disease in BD.
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1. Introduction
Behçet’s disease (BD) is an auto-inflammatory disease, characterized by recurrent painful
oral ulcerations. Diverse accompanying symptoms include uveitis, genital ulcerations, and skin
manifestations such as erythema nodosum or acneiform pustular lesions. Less common complications
include arthritis, gastro-intestinal, neurologic, or vascular involvement [1]. The clinic of BD is a
reflection of the hyperinflammatory response to external triggers in a genetically susceptible host in
which tumor necrosis factor alpha (TNF-α) may play a pivotal role. BD is proposed to be categorized
more toward the autoinflammatory spectrum rather than autoimmune disorders because of the
clinically overlapping symptoms with other autoinflammatory diseases, the enhanced inflammatory
response, and overexpression of proinflammatory cytokines, such as TNF-α [2]. Additionally, there do
not seem to exist any relevant or functional auto-antibodies in BD as in auto-immune disease. In this
both narrative and systemic review, we aimed to elucidate the role of TNF-α in BD, focusing on the
role of TNF-α in the pathogenesis and as a target for treatment.
2. Immuno-Pathogenesis of BD with Emphasis on TNF-α
The pathogenesis of BD is not yet elucidated. It is assumed that the inflammatory response in BD
is caused by stimulation of the innate immune system triggered by an external danger signal. In BD,
patients demonstrate a hyperactive adaptive immune system characterized by a disturbed Th1/Th2
balance, expansion of Th17 cells, and decreased regulatory T cells. Subsequently, there is a surplus of
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pro-inflammatory cytokines of which TNF-α may play a key role explaining the clinical symptoms [3].
This assumption is fed by a number of observations: Elevated serum and tissue TNF-α levels in BD
patients and the beneficial effect of treatment with TNF-α blocking agents [4].
TNF-α is one of the 20 members of the tumor necrosis factor superfamily (TNFSF), glycoproteins
with transmembrane regions that can also be expressed in secreted form. TNF-α is mainly secreted
by active macrophages, but also by monocytes, endothelial cells, neutrophils, smooth muscle cells,
lymphocytes, astrocytes, and adipocytes [5]. Also in BD, macrophages are not the only source of TNF-α
production. Both CD4+ and CD8+ T-cells isolated from the intestinal mucosa of BD patients produced
large amounts of TNF-α after stimulation with PMA [6]. Additionally, natural killer cells from BD
patients produce increased levels of TNF-α in periods with active disease [7].
TNF-α production is triggered by infection and inflammation and also after trauma such as burns,
myocardial infarction, or heart failure. Stimulating factors include LPS, microbiological antigens,
immune complexes, enterotoxins, superantigens, C5a anaphylatoxin, IL-1, IFN-γ, GM-CSF, TGF-β, and
autocrine mechanisms by TNF-α itself [8]. In BD, increased TNF-α production may be triggered via
an altered TLR-response. In BD, evidence is reported for an upregulation of several TLRs. Increased
expression of TLRs 2, 3, 4, and 8 has been demonstrated in PBMCs, and increased mRNA expression of
TLR2 and TLR4 has been demonstrated in oral tissue from BD patients [9,10]. After TLR activation, the
transcription factor NF-κB is activated, resulting in the production of pro-inflammatory cytokines like
TNF-α [11]. Stimulation of the upregulated TLRs with their cognate ligand in these patients did not
show an elevated TNF-α response, but this may be hampered by the immunosuppressive medication
used (corticosteroids and azathioprine) [10].
TNF-α production in BD may also be stimulated by elevated levels of IFN-γ (observed in both
serum and oral ulceration) or elevated levels of IL-1 (serum) [12–14].
The important role of TNF-α in the pathogenesis of BD is again emphasized by numerous studies
that show elevated levels of this cytokine in the serum of BD patients [15–22]. In addition, evidence is
reported for a positive correlation between TNF-α levels and disease activity [14,19,21], although other
studies did not observe such an association [15,17,20]. These differences may be explained by patient
characteristics (ethnicity) or medication usage (patients were on immunosuppressive medication in all
studies).
TNF-α is abundant in various tissues of BD patients. For example, in oral ulcers of patients with
BD, an increase in TNF-α was shown [12]. In addition, in the aqueous humor of BD patients with
uveitis, elevated TNF-α levels were observed, compared to healthy controls or BD patients without
uveitis [23,24].
In addition to this, in intestinal lesions of BD, elevated mRNA expression of TNF-α was
reported [25–27].
Other studies have not demonstrated an association with TNF-α levels in affected tissues.
For example, in the synovial fluid of BD patients with arthritis, lower levels of TNF-α than in
rheumatoid arthritis patients are reported, possibly reflecting the less severe, non-erosive form of
arthritis in BD [28,29]. In neuro-Behçet, no increase in TNF-α in cerebrospinal fluid was observed [30].
High levels of TNF-α causes shedding of the TNFR1 [31]. This soluble TNF-receptor 1 (sTNFR1)
may act as a neutralizing agent for the pro-inflammatory effects of TNF-α [32]. This negative control is
also reported in BD patients; elevated levels of sTNFR1 and sTNFR2 are observed in both the serum
and synovial fluid of BD patients with active disease [14,33,34].
TNF-α exerts its pro-inflammatory function via binding to either tumor necrosis factor receptor 1
(TNFR-1) or 2 (TNFR-2), which are able to trigger different signal pathways. The transmembrane form of
TNF-α predominantly activates TNFR-2, whereas the soluble form generally activates TNFR-1. TNFR-1
induces pro-inflammatory cytokine production via the NFκB pathway, or apoptosis via activating
caspase 8 [35]. TNFR-2 signaling is less well understood, but enables cell activation, migration, and
proliferation, mainly via activating the NFκB pathway [36,37].
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An example of TNF-α-induced cell proliferation is displayed in the expansion of the Th17
compartment, as is reported in BD. The co-culturing of Th0 cells with various pro-inflammatory
cytokines was studied, with the results directed toward IL-1β and TNF-α, to be the pivotal cytokines
in BD for differentiating a T helper cell into an IL-17-producing cell [38].
Naïve CD4+ T cells are able to differentiate into IL-22 and TNF-α-producing cells, the so-called
Th22 subsets, which develop along a distinct pathway from the Th1, Th2, or Th17 pathway. In the
presence of both IL-6 and TNF-α, these Th22 cells arise. Due to expression of the skin-homing receptors
CCR4 and CCR10, a role in inflammatory skin diseases is hypothesized [39–41]. In BD patients with
uveitis, an increase in Th22 cells was observed in serum and aqueous humor [42]. The function of
these cells was suppressed by anti-TNF-α treatment (infliximab) in vitro. Furthermore, co-culturing
with anti-TNF-α and anti-IL6 antibodies (separate and combined) prevents T cells from BD patients to
differentiate into Th22 cells [42]. In addition to this, increased expression of IL-22 after stimulation of
PBMCs is shown in BD patients with active uveitis, and another group reported increased Th22 cells in
the peripheral blood of BD patients with mucocutaneous disease [43,44].
Thus, increased levels of TNF-α stimulate T-cell development toward pro-inflammatory subsets.
Genetics of BD
Genetic predisposition to BD is considered to be polygenetic. Genome-wide association studies
(GWAS) confirmed the strong association with HLA-B51 and added IL10 and IL23R-IL12RB2 variants,
which were associated with Turkish and Japanese populations [45,46]. In addition to this, susceptibility
loci for BD at CCR1-CCR3, STAT4, KLRK1-KLRC4, and ERAP1 were reported [47]. ERAP-1 is
responsible for trimming peptides that are loaded onto the HLA protein. Polymorphisms of both
ERAP-1 and HLA could affect T- and NK-cell activation [48], which are known producers of TNF-α
in BD.
Polymorphisms of the TNF-α gene associated with BD are shown in a meta-analysis of 16 studies.
In Asian BD patients, polymorphisms in -308A/G and -857T/C were associated, which are both
associated with increased levels of TNF-α transcription [49–51]. In Caucasian BD patients, the -238A/G
and -1031C/T polymorphisms were more frequent; in addition, for the latter, there is evidence for an
increased level of TNF-α transcription [50,51].
Recently, one new study was published confirming the association between Iranian BD patients
and the 857T/C polymorphism [52]. Therefore, there is evidence for a genetic background for the
overproduction of TNF-α in BD.
3. Anti-TNF-α Treatment in BD
The ultimate confirmation of the pivotal role of TNF-α is the beneficial effect of treatment
with TNF-α blocking agents on the clinical symptoms in BD. To study this effect, we performed a
systematic review.
In this review, we will focus on infliximab, adalimumab, and etanercept. Infliximab (IFX) and
adalimumab (ADA) are both IgG1 monoclonal antibodies, which bind to TNF-α, preventing it from
activating its receptor. IFX is a mouse/human chimeric antibody, while ADA is a completely humanized
antibody. Etanercept (ETC) is a soluble p75 TNF receptor fusion protein that consists of two p75 TNF
receptors bound to the Fc portion of immunoglobulin G [53].
Given the large numbers of clinical trials and observational studies on this topic, we decided to
narrow our search to comparative studies only. This was decided to increase the quality of the included
studies and, therefore, the impact of our systematic review. BD diagnosis was defined according to the
criteria of the International Study Group of BD [54]. Methods of this systematic review are described
in detail in the supplementary data.
4. Systematic Review Into Anti-TNF-α Treatment
The reference flow is illustrated in Figure 1. The Pubmed search yielded 113 results, and searching
the Cochrane database yielded 202 results.
Int. J. Mol. Sci. 2020, 21, 3072 4 of 14
Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 4 of 17 
 
 
Figure 1. Systematic review flow diagram according to PRISMA guidelines. 
After reading the title and abstract, 11 comparative studies with TNF-α blocking agents in 
Behçet’s disease were selected for further reading. The search was validated by a second reviewer, 
adding no discrepancies. 
Four studies were prospective trails, seven were retrospective trails. In the retrospective trials, 
five compared TNF-α blocking agents with disease-modifying antirheumatic drugs (DMARDs), and 
two retrospective trails compared the starting time of IFX.  
The quality assessment of the included clinical trials and observational studies is reported in 
Supplementary Table S1 and Table S2. Melikoglu et al. [55] was judged as low risk of bias, 
Markomichelakis et al. [56], Zou et al. [57], and Martin-Varillas et al. [58] were judged at high risk of 
bias. The randomization process in the latter three caused this high risk of bias. In both 
Markomichelakis et al. and Martin-Varillas et al., there was no randomization, and the treatment 
option was determined based on a shared decision. In Zou et al., no details about the randomization 
process are described.  
All observational studies scored a low risk of bias, with the quality assessment in Miyagawa et 
al. [59] scoring 7/9 and the other studies scoring 8/9. It should be noticed that the number of patients 
included is not taken into account in the quality assessment.  
Figure 1. Systematic review flow diagram according to PRISMA guidelines.
After reading the title and abstract, 11 comparative studies with TNF-α blocking agents in Behçet’s
disease were selected for further reading. The search was validated by a second reviewer, adding
no discrepa cies.
Four studie were pros ective trails, seven retrospective trails. In the retrospective trials,
five compared TNF-α blocking agents with disease-modifying antirheumatic drugs (DMARDs), and
two retrospective trails compared the starting time of IFX.
The quality assessment of the included clinical trials and observational studies is reported
in Supplementary Table S1 and Table S2. Melikoglu et al. [55] was judged as low risk of bias,
Markom chelakis et al. [56], Zou et al. [57], and Martin-Varillas et al. [58] were judged at hig risk of
bias. The randomization process in the latter three caused this high risk of bias. In bot Markomichelakis
et al. and Martin-Varillas et al., there was no randomization, and the treatment option was determined
based on a shared decision. In Zou et al., no details about the randomization process are described.
All observational studies scored a low risk of bias, with the quality assessment in Miyagawa et
al. [59] scoring 7/9 and the other studies scoring 8/9. It should be noticed that the number of patients
included is not taken into account in the quality assessment.
4.1. Efficacy of Treatment
The results of the four prospective trials are summarized in Table 1. Overall, treatment with anti
TNF-α agents shows a positive effect on a variety of disease manifestations of BD.
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Table 1. Prospective comparative trials with anti TNF-α agents.
Author (Trial) Year Patients Study Duration ofFollow Up
Numbers
Included Outcome Treatment Comparator p-Value Adverse Events
Melikoglu 2005
Muco-
cutaneous
BD
Treatment
3 months
Treatment
group Primary outcome decrease in pathergy positivity Treatment
ETC (25 mg,
twice a week)
20 patients suppression of pathergy and
MSU
58% 58% ns
1 diarrhoedecrease in MSU, mm2
1144 944 ns
Comparator Comparatorgroup Secundary outcome
% patients free of nodular
lesions Comparator
Placebo 20 patients
difference in mean numbers
of mucocutaneous lesions
and swollen joints
85% 25% p = 0.0002 1 elevated liver
enzymes% patients free of oral ulceration
45% 5% p = 0.0017
Markomichelakis 2011 BD uveitis
Treatment
1 month
Treatment
group Primary outcome
decrease in logMAR
transformed VA Treatment
IFX 5 mg/kg
single gift 19 eyes
visual acuity, logMAR
transformed 1.2 -> 0.5 1.6 -> 0.7 ns None
Comparator Comparatorgroup Secundary outcome decrease in total inflammation score Comparator
CCS* 8/8 eyes ao total inflammation score largest decrease in IFX on day 14 p = 0.010
ocular hypertension
in 4 triamcinolon
treated eyes
Zou 2017 Intestinal BD
Treatment
30 weeks
Treatment
group Primary outcome corticosteroid-free clinical remission, no (%) Treatment
IFX 3.5 mg/kg 10 patients corticosteroid-free clinicalremission 4 (40%) 6 (60%) p = 0.371
1 eczema; topical
therapy and 1
common cold
Comparator Comparatorgroup Secundary outcome mucosal healing at week 14, no (%) Comparator
IFX 5 mg/kg 10 patients endoscopic mucosal healing 6 (60%) 6 (60%) p = 1.0 none
Martin Varillas 2018 BD uveitis
Treatment
34 months
Treatment
group Primary outcome
relapses, n (per 100
patients/year) Treatment
ADA optimized
dose 23 patients relapse of uveitis 2 (3.0) 4 (4.4) p = 0.66 None
Comparator
26 months
Comparator
group Secundary outcome costs (mean), euros per year Comparator
Non optimized
ADA 42 patients costs 6101,25 12339,48 p < 0.01
lymphoma,
pneumonia, Ecoli,
local reaction (1
each)
Abbreviations used: ADA adalimumab, CCS corticosteroids, ETC etanercept, IFX infliximab, MSU monosodium urate, VA visual acuity; * 3 d iv 1 g methylprednisolone or 4 mg
triamcinolone intra-vitreal.
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Melikoglu et al. [55] is the only trial comparing TNF-α blocking treatment (i.e. ETC) with placebo.
This trial only included male patients (because BD is thought to be more severe in men) and compared
the treatment of 20 patients with ETC 25 mg, twice a week for four weeks, to placebo treatment. This
study was designed to evaluate possible suppression of the pathergy and monosodium urate (MSU)
test by ETC. Intradermal injection with MSU tests skin hyperreactivity, in analogy with the pathergy
test. A suppressive effect was not detected, but a significant decrease in nodular lesions and oral
ulceration in the ETC group was noticed.
Markomichelakis et al. [56] treated 22 BD patients with uveitis (35 eyes) with either a single
gift of IFX or corticosteroids (1 g iv methylprednisolone for 3 d or 4 mg triamcinolone intra-vitreal).
This study also did not meet their primary objective; there was no difference in the decrease in logMAR
transformed visual acuity. In one of the secondary outcomes, a significantly larger decrease in total
inflammation score in the eyes in the IFX group compared to the corticosteroid group was reported.
The total inflammation score consists of the counting of cells in the different segments of the eye and of
the presence of vasculitis, papillitis, and retinal cystoid macular edema.
Both Zou [57] et al. and Martin-Varillas [58] et al. compare different dosages of anti-TNF-α
treatment. Both groups provide evidence for a comparable efficacy in treatment with a lower or
reduced dose.
Zou et al. compared IFX dosed at 3.5 mg/kg with IFX dosed at 5 mg/kg administered at 0, 2, and 6 w
in 20 patients with intestinal BD. After 30 w of follow up, at both primary outcome (corticosteroid-free
clinical remission) and secondary outcome (endoscopic mucosal healing), no significant differences
were reported between both groups. Martin-Varillas et al. studied optimizing the dose of ADA in BD
uveitis patients in remission on ADA treatment. Forty-two patients with 40 mg/2 w were compared to
23 patients in which, every 3 months, the dosing interval was prolonged, initially every 3 w, and then
every 4, 6, and 8 w up to discontinuation. They report a comparable number of relapses of uveitis per
100 patients per year, but a significant decrease in costs.
There are three retrospective trials comparing IFX with a DMARD in BD patients with uveitis
(Table 2).
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Table 2. Retrospective comparative trials with anti TNF-α agents and DMARDs.
Author
(Trial) Year Patients Study
Duration of
Follow Up
Numbers
Included Outcome Treatment Comparator p-Value Adverse Events
Tabbara 2008 BD uveitis
Treatment
36 months
Treatment Primary outcome Mean no. of relapses (range) Treatment
IFX*, CCS,
AZA 10 patients number of relapse
1.2 (0 to
4) 6.3 (4 to 7) p < 0.001
2 mild infusion reactions, 1
infection (perianal abces)
Comparator
30 months
Comparator Secundary outcome Patients with good BCVA¥ (%) Comparator
CCS, CsA,
AZA, MTX 33 patients BCVA 50% 6% p = 0.0059
4 hypertension, 5 renal function
decrease, 3 elevated liver
enzymes, 7 hyperglycemia
Yamada 2010 BD uveitis
Treatment
6 months
Treatment Primary outcome Mean no. of relapses (SD) Treatment
IFX** 17 patients number of relapse 0.4(±1.0) 1.2 (±1.2) p < 0.05
9 skin symptoms (eruptions,
itching, atopic dermatitis); topical
therapy
Comparator Comparator Secundary outcome Improved/unchanged BCVA (%) Comparator
CsA 20 patients BCVA 97% 93% ns 1 neurologic symptoms and renaltoxicity; dose reduction
Takeuchi 2012 BD uveitis
Treatment
25 months
Treatment Primary outcome Mean no. of relapses/6 months(SD) Treatment
IFX** 7 patients number of relapse 0.22(±0.28) 0.18 (±0.19) ns 1 infusion reaction
Comparator
33 months
Comparator Secundary outcome Improved/unchanged BCVA (%) Comparator
IFX**,
colchicine 7 patients BCVA 100% 83.3% ns
CMV infection; cured by
valganciclovir
Emmi 2018 Vascular
BD
Treatment
26 months
Treatment Primary outcome Complete or partial response, no(%) Treatment
ADA 35 patients vascular response(ultrasound)
34
(97.1%) 23 (66%) p = 0.001
2 urticarial skin rash, 1
pneumonia, 1 HSV reactivation
Comparator Comparator Secundary outcome Mean time (SD), weeks Comparator
DMARDs 35 patients time to achievevascular response
3.7
(±1.7) 6.3 (±1.2) p < 0.0001 2 adverse events
Miyagawa 2019 Intestinal
BD
Treatment
12 months
Treatment Primary outcome Patients with cured ulcer, no (%) Treatment
TNF-i with
CCS 20 patients
ulcer cure rate
(endoscopic)
12
(60%)
13
(45%) 3 (13.6%) 1 bacterial infection
Comparator Comparator Secundary outcome Patients with improvement of ulcer, no (%) Comparator
TNF-i without
CCS 29 patients
ulcer improvement
rate
12
(60%)
15
(57%) 6 (27%) none described
Comparator Comparator Comparator
CCS 22 patients
Abbreviations used: ADA adalimumab, AZA azathioprine, BCVA best corrected visual acuity, CCS corticosteroids, CsA cyclosporin A, CMV cytomegalovirus, DMARDs disease-modifying
anti-rheumatic drugs, HSV herpes simplex virus, IFX infliximab, MTX methotrexate, SD standard deviation. * = (5 mg/kg) day 1 and at 2, 4, 6, 8, and 10 weeks; ** = (5 mg/kg) day 1 and at 2,
4, 6, and 8 weeks; ¥ = 20/50 or better.
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Tabbara et al. [60] and Yamada et al. [61] both compared DMARD treatment (Tabbara et al.,
corticosteroids, cyclosporin A, methotrexate, and azathiopirin; Yamada et al., cyclosporine A) with
IFX 5 mg/kg treatment. Tabbara et al. differed in a longer follow up (30–36 months) from Yamada
et al. (6 months). Both these studies reported a significant decrease in the number of relapses of
uveitis in patients treated with IFX compared to DMARDs. To compare the number of relapses, we
have calculated the number of relapses per 6 months, which is, in Tabbara et al., 1.6 for the DMARD
group and 0.3 for the IFX group. These numbers are comparable to Yamada et al., 1.2 in the DMARD
group and 0.4 in the IFX group. Both studies reported the best corrected visual acuity (BCVA) as a
secondary outcome. Tabbara et al. observed a significantly larger percentage of patients with a good
BCVA (defined as 20/50 or better) in the IFX group. Yamada et al. observed a comparable percentage
of improved and unchanged BCVA between the IFX group and the DMARD group.
Takeuchi et al. [62] compared IFX monotherapy with IFX combined to colchicine in 14 patients
with BD uveitis. After a median follow-up period of 25 months, no significant difference in uveitis
relapse per 6 months was noticed. In addition, measured in BCVA, no added value of colchicine
treatment was found.
In 70 BD patients with vascular involvement, Emmi et al. [63] compared ADA with DMARD
treatment. Measured by ultrasound, the percentage of complete or partial response of the vascular
lesions was significantly higher in the ADA treatment group. In addition to this, the mean time to
achieve the vascular response was almost 3 w shorter in the ADA treatment group.
Miyagawa et al. [59] compared the effectiveness of anti-TNF-α treatment with corticosteroids.
Next to this, the additive value of corticosteroids to anti-TNF-α treatment was studied. In total,
71 patients with intestinal BD were followed for 12 months. Efficacy was studied by endoscopic
evaluation of intestinal ulceration. The percentage of cure rate was significantly better with TNF
treatment compared to corticosteroids (p = 0.0029). Adding corticosteroids to TNF treatment caused
no significant further improvement in cure rate of intestinal ulceration. This is also observed for the
percentage of improved intestinal ulcers.
We have reviewed two retrospective studies comparing the starting time of IFX treatment in
patients with BD uveitis (Table 3). Keino et al. [64] compared, in 13 BD patients with uveitis, IFX
treatment starting within 18 months of the onset of ocular disease to IFX treatment starting after
18 months. In a number of relapses, no significant differences were observed between early or late
IFX treatment. Early treatment did show a significant decrease in disc and retinal leakage scores; in
addition to this, BCVA was significantly better in the early treatment group. This last result should be
interpreted with caution, because baseline characteristics of the early treatment group regarding BCVA
were also significantly better compared to the late treatment group.
Guzelant et al. [65] compared treatment with IFX for uveitis with their own historical cohort
(before and after January 2013). In the new cohort, they initiated IFX treatment significantly earlier
in the disease course (36 vs. 72 months). This resulted in significantly better results in BCVA (stable
visual acuity in 64% in new cohort vs. 28% of patients in old cohort) and in a significant decrease in
relapses (7% in new cohort vs. 53% in old cohort).
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Table 3. Retrospective trials comparing infliximab in starting time.
Author
(Trial) Year Patients Study
Duration of
Follow Up
Numbers
Included Outcome Treatment Comparator p-Value Adverse Events
Keino 2017 BD uveitis
Treatment
24 months
Treatment Primary outcome Mean no. of relapses/6 months(SD) Treatment
Uveitis <18
months 6 patients number of relapse no significant differences 5 viral infection
Comparator Comparator Secundary outcome Vascular leakage score Comparator
Uveitis >18
months 7 patients
ao vascular leakage
score
significant decrease in
<18mcompared to >18m after
year 1 and 2
1 viral infection, 1 bacterial
pharyngitis responding to
antibiotic therapy
Guzelant 2017 BD uveitis
Treatment
12 months
Treatment Primary outcome Stable VA after IFX in R eye, n (%) Treatment
After January
2013 14 patients BCVA 9 (64) 12 (28) p = 0.01
3 allergic reactions, 1 pulmonary
TBC
Comparator
40 months
Comparator Secundary outcome Number of relapses, n (%) Comparator
Before January
2013 43 patients number of relapse 1 (7)
23
(53.4) p = 0.002
2 allergic reactions, 1 pulmonary
TBC, 1 lung nodule
Abbreviations used: BCVA best corrected visual acuity, IFX infliximab, TBC tuberculosis, SD standard deviation.
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4.2. Adverse Events
TNF-α blocking treatment is mostly associated with infections, allergic reactions, or skin reactions
and malignancies.
In this systematic review, in all articles, 313 patients were treated with one of three different
anti-TNF-α agents. Seventeen patients were described with infections (5%), majority viral (nine
patients), six patients with bacterial infections, and two cases of pulmonary tuberculosis (despite
screening and INH treatment). Eight patients suffered allergic reactions, all after infusion of IFX (2.5%).
One malignancy (lymphoma) was described, and 12 patients experienced skin reactions after treatment
with an anti-TNF-α agent. No deaths due to adverse events were observed.
5. Discussion
In this both narrative and systemic review, we discuss the role of TNF-α in Behçet’s disease.
TNF-α has a pivotal role in the immunopathogenesis of BD. Here, we report of increased production of
TNF-α by macrophages, CD4+ and CD8+ T-cells, and NK-cells in patients with BD [6,7]. This increased
production may be stimulated via TLR-signaling, or triggered by the increased levels of IL-1β and
IFN-γ, which are observed in serum of BD patients [9,10,12–14]. The abundance of TNF-α is found in
both serum and in sites of inflammation such as oral ulceration, intestinal ulceration, and the aqueous
humor of patients with BD uveitis [14–24]. In serum, there may be a positive correlation between
the levels of TNF-α and disease activity, although there is also evidence that argues against this.
The inconsistency may be explained by the heterogeneity in patient cohorts and immunosuppressive
medication used. The increased presence of TNF-α in serum and tissue stimulates T-cell development
toward pro-inflammatory subsets, such as Th17 and Th22 cells [38,42].
In the systematic review, we add data about the effects of treatment with TNF-α blocking agents
on the course of BD. We observe an overall beneficial effect of treatment with TNF-α blocking agents
on the various manifestations of BD. Unfortunately, this observation is not based on high-quality
prospective randomized control trials. Only four prospective trials could be included, where three
were assessed at high risk of bias. This was caused by demerits in the randomization process. Despite
the risk of bias, all studies display the value of treatment with anti-TNF-α agents in BD.
The retrospective observational studies included in this systematic review were all of high quality.
Four studies compared anti-TNF-α treatment with DMARDs. These studies observed significant
beneficial effects on uveitis (decrease in mean number of relapses), intestinal BD (increased ulcer cure
rate), and vascular BD (increase in vascular response on ultrasound examination). Takeuchi et al.
showed no additional value of colchicine treatment next to IFX in a small cohort of BD uveitis patients.
Early initiating of IFX treatment was evidenced to be effective in increasing BCVA and in decreasing
the number of relapses by Guzelant et al. In a small cohort of 13 BD patients, Keino et al. observed no
difference in the number of relapses of uveitis in patients starting IFX treatment within 18 months of
onset of ocular disease or IFX treatment starting after 18 months.
Despite the risk of bias in the prospective trials, we can conclude that treatment with anti-TNF-α
agents (especially IFX and ADA) has a beneficial effect on the course of disease in BD. This is
evidenced in uveitis, intestinal, and vascular BD. The clinical effects were achieved with a relatively
low incidence of adverse effects. Infections (5%) are most common, followed by allergic reactions
(2.5%). In 313 patients, one malignancy was reported (lymphoma).
The broad spectrum of symptoms that are alleviated by treatment with anti-TNF-α agents confirms
the major role of TNF-α in the diverse manifestations of BD. Blocking of TNF-α downregulates
pro-inflammatory T-cell subsets and restores the memory B-cell compartment [66–68]. Next to the
immunologic effects of anti-TNF-α treatment, the beneficial effect on vascular BD disease suggests an
effect on the vascular endothelial cells, but this is not yet evidenced in BD.
There are several limitations to our systematic review. Due to the heterogeneity of outcome
measurements, we were unable to perform a meta-analysis. In addition, prefiltering on comparative
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studies caused a relatively low number of studies to be eligible for inclusion. Next to this, the included
retrospective studies have the potential risk of selection bias.
Nevertheless, our systematic review has several strengths. First, we only included comparative
studies to increase the quality of our review. Second, all retrospective studies included were of high
quality. Third, this is the first review study specifically aimed at TNF-α in BD, describing the role in
pathogenesis and the clinical effects of treatment with TNF-α blocking treatment.
In conclusion, we present a both narrative and systematic review focused on TNF-α in BD. The
pivotal role of TNF-α in the immunopathogenesis of BD is reflected by the increased production of
TNF-α by macrophages, CD4+ and CD8+ T-cells, and NK-cells and by the increased levels of TNF-α in
serum and in inflamed tissue. Treatment directed against this cytokine is evidenced to positively affect
the course of disease in BD.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/9/3072/s1.
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